Selexipag for treating pulmonary arterial hypertension

Published on 13 Sep 2024
Last Updated on 13 Sep 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended selexipag for inclusion on the MOH List of Subsidised Drugs as an add-on therapy for patients with pulmonary arterial hypertension who are insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor. The decision was based on the unfavourable cost effectiveness of selexipag compared with placebo at the prices proposed by the company.  

Selexipag for treating pulmonary arterial hypertension (Published 13 Sep 2024) [PDF, 132 KB]

PES Selexipag for treating pulmonary arterial hypertension (Published 13 Sep 2024) [PDF, 96 KB]